As per newly released report from Absolute Market Insights (AMI), the global cystic fibrosis market was valued at US$ 9,839.9 Mn in 2019, owing to rising advancements in testing that are likely to create new channels for growth for players in the global cystic fibrosis market. On June 8, 2021, the U.S. Food and Drug Administration approved the Trikafta medicine for children aged 6 and above. Earlier, the dose of the medicine was limited for children above 12 years of age. The new approval is a major step towards the treatment of much younger patients. Trikafta was earlier approved in 2019 however, new approval is likely to help the parent company, Vertex prevent spread of the devasting life-threatening condition among nearly 1,500 new children in the U.S. alone. Furthermore, the medicine has already been approved for children above 12 years in the UK, Australia and Israel, amongst others. Vertex plans on filling an appeal in more countries to extend the use to children aged 6 and above immediately. The growing availability of the new medicine for children aged 6, and its promising expansion in new regions is likely to result in varied new opportunities for marketing, production, testing, and manufacturing of the medicine in the new regions. These factors are driving the growth of cystic fibrosis market. The U.S. is witnessing a growing debate among legislators to include cystic fibrosis in the list of mandatory conditions to test all newborn children. Currently, about 4 million newborns in the U.S. are undergoing mandatory screening for various diseases. It is estimated that about 12,000 of these are diagnosed with various rare diseases like cystic fibrosis. This medical debate is soon likely to shift in the favor of players in the cystic fibrosis market. Advancements in genetic testing have made it easier to detect conditions like cystic fibrosis accurately within a small-time frame. Moreover, cystic fibrosis is not only a life-threatening condition, there are 12 million estimated U.S. adults living with one defective gene out of 2 found in cystic fibrosis patients. The public and private interest in the detection of cystic fibrosis is also growing. This partially is due to the growing interest in DNA testing, and new grant support offered by FDA for treatment of rare diseases globally. An example of this growing interest is BillionToOne. In 2021, BillionToOne, a healthcare startup working towards detection of muscular atrophy, and cystic fibrosis received a $55 million in series B funding. Its signature test named Unity tests for cystic fibrosis accurately tests fetuses through maternal blood samples. Such growing innovation in the area of genetic testing, growing research interest in cystic fibrosis, and rising interest among legislators is likely to drive tremendous growth opportunities for players in the cystic fibrosis market in the near future.
Access the Full Report @ https://industryglobalnews24.com/global-cystic-fibrosis-market-to-grow-at-promising-773-cagr
Cystic fibrosis is a rare condition. Hence, its toll and burden often drives individual patients in isolation. Furthermore, this genetic condition can require 2 to 4 hours everyday to clear mucus, and constantly face co-morbidities including liver and diabetes. It also affects children at a really young age – the condition remains a nightmare for mental health of caregivers like parents globally. Hence, increased attempt to tackle challenges like depression among caregivers are expected to arise in the near future. Mental health ailments like depression are increasingly making their way into the open, with less social stigma and growing acceptance in the world today. Furthermore, as awareness about cystic fibrosis increases, and caregivers find more cost-effective solutions like TMS therapy to tackle mental health, the cystic fibrosis market is likely to witness new avenues of growth opportunities for existing players in the matured markets of North America and Europe. The cystic fibrosis market remains a consolidated, and yet innovative landscape, thanks to increased focus on rare conditions by the FDA, among various other stakeholders. Some key players in the global cystic fibrosis market are Aradigm Corporation, AbbVie Inc, CHIESI Farmaceutici S.p.A., Demegen, Inc., Celtaxsys Aus Pty Limited, Gilead Sciences, Inc, F. Hoffmann-La Roche Ltd and GlaxoSmithKline Plc. amongst others.
The covid-19 pandemic has not resulted in increased fatalities, or severe progression of cystic fibrosis among patients yet. However, researchers believe this is largely due to extra precautions maintained by patients with cystic fibrosis. During the 2009 H1N1 pandemic, higher morbidities were often experienced by patients with cystic fibrosis. Furthermore, this pandemic has brought attention to co-existing morbidities like diabetes and lung infection. These are on the rise globally, and also present a potentially challenging scenario for global healthcare infrastructure. This is partially why investment in research during the covid-19 pandemic on cystic fibrosis condition is rising significantly. The increased studies report a strong possible connection between patients with cystic fibrosis, and patients with diabetes. For example, a study published in June 2021 in cystic fibrosis journal states that reduced level VIP hormones in the pancreas may lead to diabetes among patients with cystic fibrosis. Growing interest in understanding chronic diseases like diabetes, its increased association with cystic fibrosis, and increased interest in research for CF promises major growth for players in the global cystic fibrosis market during the 2021-2030 period.
Cystic Fibrosis Market:
By Drug Class
- CFTR modulators
- Mucolytics (Mucoactive Drugs) and Bronchodilators
- Pancreatic Enzyme Replacement Therapy (PERT)
By Route of Administration
By Distribution Channel
- Offline Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Middle East & Africa
- Latin America
Company: Absolute Markets Insights
Email id: firstname.lastname@example.org
Contact Name: Shreyas Tanna